BRPI0722053A2 - método para o tratamento de câncer, formulação anticâncer, método de uso da formulação, e, uso de metoxiamina - Google Patents

método para o tratamento de câncer, formulação anticâncer, método de uso da formulação, e, uso de metoxiamina

Info

Publication number
BRPI0722053A2
BRPI0722053A2 BRPI0722053A BRPI0722053A BRPI0722053A2 BR PI0722053 A2 BRPI0722053 A2 BR PI0722053A2 BR PI0722053 A BRPI0722053 A BR PI0722053A BR PI0722053 A BRPI0722053 A BR PI0722053A BR PI0722053 A2 BRPI0722053 A2 BR PI0722053A2
Authority
BR
Brazil
Prior art keywords
formulation
methoxyamine
cancer treatment
anticancer
treatment method
Prior art date
Application number
BRPI0722053A
Other languages
English (en)
Inventor
Jean Adams Bonne
P Theuer Charles
Original Assignee
Tracon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39775383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0722053(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tracon Pharmaceuticals Inc filed Critical Tracon Pharmaceuticals Inc
Publication of BRPI0722053A2 publication Critical patent/BRPI0722053A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0722053A 2006-12-29 2007-12-21 método para o tratamento de câncer, formulação anticâncer, método de uso da formulação, e, uso de metoxiamina BRPI0722053A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87783606P 2006-12-29 2006-12-29
US88326607P 2007-01-03 2007-01-03
US88395907P 2007-01-08 2007-01-08
PCT/US2007/088666 WO2008083107A2 (en) 2006-12-29 2007-12-21 Antifolate agent combinations in the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0722053A2 true BRPI0722053A2 (pt) 2018-04-17

Family

ID=39775383

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0722053A BRPI0722053A2 (pt) 2006-12-29 2007-12-21 método para o tratamento de câncer, formulação anticâncer, método de uso da formulação, e, uso de metoxiamina

Country Status (15)

Country Link
US (1) US8017618B2 (pt)
EP (1) EP2173333B1 (pt)
JP (1) JP5249239B2 (pt)
KR (1) KR101195366B1 (pt)
CN (2) CN102014887A (pt)
AU (1) AU2007339918B2 (pt)
BR (1) BRPI0722053A2 (pt)
CA (1) CA2674075C (pt)
ES (1) ES2688938T3 (pt)
GB (1) GB2453011B (pt)
HK (1) HK1215683A1 (pt)
IL (1) IL199609A0 (pt)
MX (1) MX2009007144A (pt)
NO (1) NO344316B1 (pt)
WO (1) WO2008083107A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130689A1 (en) * 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
US10725042B2 (en) * 2012-05-22 2020-07-28 Case Western Reserve University Methods of diagnosing and treating cancer
JP2014001204A (ja) * 2012-05-23 2014-01-09 Kumamoto Univ 腫瘍細胞選択的抗がん剤
JP6615746B2 (ja) 2013-04-09 2019-12-04 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 腫瘍選択的併用療法
US20160051679A1 (en) * 2013-04-12 2016-02-25 Actavis Group Ptc Ehf. Pemetrexed Formulation
EP3328387B1 (en) * 2015-07-30 2020-07-22 Expression Pathology, Inc. Quantifying fr- and gart proteins for optimal cancer therapy
CN121177507A (zh) 2016-08-12 2025-12-23 L.E.A.F.控股集团公司 α和γ-D聚谷氨酸化抗叶酸剂及其用途
WO2018147437A1 (ja) * 2017-02-10 2018-08-16 学校法人神戸学院 低分子医薬化合物の経粘膜吸収促進剤
KR102040034B1 (ko) * 2017-12-13 2019-11-05 주식회사 아이큐어비앤피 페메트렉시드를 포함하는 경구용 약학 조성물 및 이의 제조방법
WO2019157121A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated lometrexol and uses thereof
JP7491572B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化ペメトレキセドおよびその使用
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
EP3749319A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES
EP3749314A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATE METHOTREXATE AND ITS USES
WO2019157145A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
EP3749321A4 (en) * 2018-02-07 2022-03-09 L.E.A.F Holdings Group LLC Gamma polyglutamated antifolates and uses thereof
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
US12310966B2 (en) 2018-02-07 2025-05-27 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
JP7462950B2 (ja) 2018-02-14 2024-04-08 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化メトトレキセートおよびその使用
US12350271B2 (en) 2018-02-14 2025-07-08 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
WO2019160735A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
CA3090753A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406917B1 (en) * 1996-06-11 2002-06-18 Advanced Research And Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
EP0923738A1 (en) * 1996-06-11 1999-06-23 Advanced Research & Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
AU2003209060A1 (en) * 2002-02-07 2003-09-02 Axys Pharmaceuticals, Inc. Assay for acytyltransferase or deacetylase activity
GB2385523B (en) * 2002-02-25 2004-01-07 Ronan Anthony Byrne Descent apparatus
US7785578B2 (en) * 2002-10-11 2010-08-31 Aciont, Inc. Non-invasive ocular drug delivery
GB0226370D0 (en) * 2002-11-12 2002-12-18 Novartis Ag Organic compounds
AU2004274013A1 (en) * 2003-09-17 2005-03-31 Icos Corporation Use of Chk1 inhibitors to control cell proliferation
PL2305221T3 (pl) * 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
US8246949B2 (en) * 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
WO2007038687A2 (en) * 2005-09-27 2007-04-05 Aciont, Inc. Ocular administration of immunosuppressive agents
WO2007041593A2 (en) * 2005-10-03 2007-04-12 Combinatorx, Incorporated Anti-scarring drug combinations and use thereof
CN100500215C (zh) * 2006-01-23 2009-06-17 济南帅华医药科技有限公司 含氨甲喋呤及其增效剂的缓释注射剂

Also Published As

Publication number Publication date
GB2453011A (en) 2009-03-25
JP5249239B2 (ja) 2013-07-31
CN104958299A (zh) 2015-10-07
CN102014887A (zh) 2011-04-13
AU2007339918A1 (en) 2008-07-10
KR101195366B1 (ko) 2012-11-21
GB0812013D0 (en) 2008-08-06
NO344316B1 (no) 2019-11-04
EP2173333A2 (en) 2010-04-14
MX2009007144A (es) 2009-12-18
KR20090110843A (ko) 2009-10-22
CA2674075C (en) 2012-10-30
EP2173333B1 (en) 2018-06-27
IL199609A0 (en) 2010-05-17
HK1215683A1 (zh) 2016-09-09
JP2010538967A (ja) 2010-12-16
WO2008083107A2 (en) 2008-07-10
US20080234298A1 (en) 2008-09-25
AU2007339918B2 (en) 2011-06-02
CA2674075A1 (en) 2008-07-10
ES2688938T3 (es) 2018-11-07
WO2008083107A3 (en) 2010-01-21
US8017618B2 (en) 2011-09-13
NO20092616L (no) 2009-09-22
GB2453011B (en) 2010-06-23

Similar Documents

Publication Publication Date Title
BRPI0722053A2 (pt) método para o tratamento de câncer, formulação anticâncer, método de uso da formulação, e, uso de metoxiamina
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
CL2008002381A1 (es) Oligonucleotido inmunoestimulador; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno o afeccion en un sujeto, incluyendo cancer.
BRPI0820212A2 (pt) Dispositivo para tratamento de fraturas, método para tratamento de fraturas, e, kit para tratamento de fraturas
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0816318A2 (pt) Dispositivo de liberação transdérmica, e, método para preparar o mesmo
BRPI0821276A2 (pt) Produto, e, uso do produto
BRPI0716210A2 (pt) Métodos, composições e aparelhos para tratar feridas com pressões diferentes da atmosférica
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0908100A2 (pt) produto combinação, uso de um composto, e, método de tratar câncer
BRPI0816214A2 (pt) Uso cosmético, composição cosmética e/ou dermatológica, e, métodos para o tratamento cosmético da pele, para o tratamento cosmético de sinais cutâneos de envelhecimento e/ou fotoenvelhecimento e para o tratamento cosmético para prevenir e/ou tratar substâncias queratinosas secas
BRPI0718688A2 (pt) Composições de baixa irritação e métodos para preparar as mesmas.
IL230076A0 (en) Certain chemical entities, compositions and methods
BRPI0719732A2 (pt) nanopartículas de peptídeo e usos para as mesmas
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BR112012004281A2 (pt) uso de metformina tratamento e prevenção de câncer
BRPI0818287A2 (pt) células dendríticas manipuladas e usos para o tratamento do câncer.
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0914343A2 (pt) composição, produto, uso da composição e método
BRPI1007779A2 (pt) perexilina, método para tratamento de hcm, programa de tratamento para tratar hcm e uso da perexilina
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.